
Claims

1. Use of a compound of Formula I:





I

or a pharmaceutically acceptable salt thereof,

wherein:

X is -O-;

Y is  or ;

R^1 and R^2 are each hydrogen;

R^3 and R^4 are each independently selected from hydrogen and halo, and when one of R^3 or R^4 is halo, the other of R^3 or R^4 is hydrogen;

R^5 is C_1-C_6 alkyl or C_1-C_6 haloalkyl;

R^6 is C_1-C_6 haloalkyl; and

R^7 and R^8 are each independently selected from hydrogen and C_1-C_6 alkyl;

in the manufacture of a medicament for treating a subject suffering from a disorder mediated by the estrogen receptor.

2. The use of claim 1, wherein the disorder mediated by the estrogen receptor is estrogen receptor-associated cancer.

3. The use of claim 1, wherein the disorder mediated by the estrogen receptor is breast cancer.

4. The use of claim 2, wherein the medicament is for treating in combination with an additional anti-cancer agent.

5. The use of claim 4, wherein the additional anti-cancer agent is selected from an mTOR inhibitor, a CDK4/6 inhibitor, a PI3 kinase inhibitor, an aromatase inhibitor, an antibody to or inhibitor of PD-1, PD-L1 or CTLA-4, or an antibody to or inhibitor of EGFR, PGFR, or IGFR.

6. The use of claim 5, wherein the additional anti-cancer agent is an mTOR inhibitor.

7. The use of claim 6, wherein the mTOR inhibitor is selected from everolimus and rapamycin.

8. The use of claim 5, wherein the additional anti-cancer agent is a CDK4/6 inhibitor.

9. The use of claim 8, wherein the CDK4/6 inhibitor is selected from palbociclib, abemaciclib and ribociclib.

10. The use of claim 5, wherein the additional anti-cancer agent is an antibody or inhibitor of PD-1, PD-L1 or CTLA-4.

11. The use of claim 5, wherein the additional anti-cancer agent is an antibody or inhibitor of EGFR, PGFR, or IGFR.

12. The use of claim 4, wherein the additional anti-cancer agent is selected from trastuzumab, pertuzumab, ado-trastuzumab, trastuzumab emtansine, erlotinib, gefitinib, and neratinib.

13. The use of claim 5, wherein the additional anti-cancer agent is a PI3 kinase inhibitor.

14. The use of claim 13, wherein the PI3 kinase inhibitor is selected from perifosine, CAL101, BEZ235, XL147, XL765, GDC-0941, and IPI-145.

15. The use of claim 5, wherein the additional anti-cancer agent is an aromatase inhibitor.


16. The use of claim 15, wherein the aromatase inhibitor is selected from aminoglutethimide, testolactone, anastrozole, letrozole, exemestane, vorozole, formestane, fadrozole, 4-hydroxyandrostenedione, 1,4,6-androstatrien-3, 17-dione, and 4-androstene-3,6, 17-trione.

17. The use of claim 15, wherein the aromatase inhibitor is selected from anastrozole, letrozole, and exemestane.

18. The use of claim 1, wherein Y is .


19. The use of claim 18, wherein R^5 is C_1-C_6 alkyl.

20. The use of claim 1, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

21. A composition comprising a compound:

,

or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier.